96 related articles for article (PubMed ID: 25439387)
21. Granulomatous Lymphocytic Lung Interstitial Disease (GLILD): A Diagnostic Challenge. Report of Three Cases.
Briones Alvarado SI; Liendo Martínez KH; Galindo Guzman H; Caballero Segura F; Pedraza F
Arch Bronconeumol; 2024 Feb; 60(2):110-112. PubMed ID: 38158279
[No Abstract] [Full Text] [Related]
22. Successful rituximab treatment of granulomatous/lymphocytic interstitial lung disease in common variable immunodeficiency.
Králíčková P; Kubcová Š; Kočová E; Bartoš V; Souček O; Rozsíval P; Vaníček H; Krčmová I; Ravčuková B; Grombiříková H; Freiberger T
Epidemiol Mikrobiol Imunol; 2018; 67(3):142-148. PubMed ID: 30602282
[TBL] [Abstract][Full Text] [Related]
23. Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review.
Lamers OAC; Smits BM; Leavis HL; de Bree GJ; Cunningham-Rundles C; Dalm VASH; Ho HE; Hurst JR; IJspeert H; Prevaes SMPJ; Robinson A; van Stigt AC; Terheggen-Lagro S; van de Ven AAJM; Warnatz K; van de Wijgert JHHM; van Montfrans J
Front Immunol; 2021; 12():606099. PubMed ID: 33936030
[TBL] [Abstract][Full Text] [Related]
24. Granulomatous-lymphocytic interstitial lung disease: A pulmonary complication of common variable immunodeficiency.
Matesanz López C; Raboso Moreno B; Río Ramírez MT
Med Clin (Barc); 2023 Jun; 160(11):e1-e2. PubMed ID: 36801147
[No Abstract] [Full Text] [Related]
25. Raised Serum Markers of T Cell Activation and Exhaustion in Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency.
Fraz MSA; Michelsen AE; Moe N; Aaløkken TM; Macpherson ME; Nordøy I; Aukrust P; Taraldsrud E; Holm AM; Ueland T; Jørgensen SF; Fevang B
J Clin Immunol; 2022 Oct; 42(7):1553-1563. PubMed ID: 35789314
[TBL] [Abstract][Full Text] [Related]
26. Common variable immunodeficiency-associated granulomatous and lymphocytic interstitial lung disease successfully treated with a combination regimen of rituximab and azathioprine.
Moctezuma SI; Panizo CM; Landecho MF
Med Clin (Barc); 2017 Oct; 149(7):312-313. PubMed ID: 28736065
[No Abstract] [Full Text] [Related]
27. Common Variable Immune Deficiency and Associated Complications.
Gupta S; Pattanaik D; Krishnaswamy G
Chest; 2019 Sep; 156(3):579-593. PubMed ID: 31128118
[TBL] [Abstract][Full Text] [Related]
28. Granulomatous-Lymphocytic Interstitial Lung Disease in 22q11.2 Deletion Syndrome: a Case Report and Literature Review.
Sood AK; Funkhouser W; Handly B; Weston B; Wu EY
Curr Allergy Asthma Rep; 2018 Feb; 18(3):14. PubMed ID: 29470661
[TBL] [Abstract][Full Text] [Related]
29. Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency: Methodological issues.
Ayubi E; Safiri S
Ann Allergy Asthma Immunol; 2017 Sep; 119(3):296. PubMed ID: 28890025
[No Abstract] [Full Text] [Related]
30. Rituximab as a single agent for successful treatment of granulomatous and lymphocytic interstitial lung disease in a pediatric patient with common variable immunodeficiency.
Kosinski SM; Nachajon RV; Milman E
J Allergy Clin Immunol Pract; 2022 Mar; 10(3):876-878.e1. PubMed ID: 34718215
[No Abstract] [Full Text] [Related]
31. Rituximab as a Single Agent for Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immune Deficiency.
Tessarin G; Bondioni MP; Rossi S; Palumbo L; Soresina A; Badolato R; Plebani A; Lougaris V
J Investig Allergol Clin Immunol; 2019 Dec; 29(6):470-471. PubMed ID: 31825316
[No Abstract] [Full Text] [Related]
32. Immunodeficiency in the differential diagnosis of interstitial lung diseases.
Doubková M; Špeldová J; Chovancová Z
Vnitr Lek; 2019; 65(11):685-693. PubMed ID: 31906674
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency.
Cereser L; De Carli R; Girometti R; De Pellegrin A; Reccardini F; Frossi B; De Carli M
J Allergy Clin Immunol Pract; 2019 Mar; 7(3):1055-1057.e2. PubMed ID: 30408616
[No Abstract] [Full Text] [Related]
34. Granulomatous skin lesions of common variable immunodeficiency treated with sirolimus.
Lee AY; Huynh N; Lin MW
Australas J Dermatol; 2021 Aug; 62(3):434-435. PubMed ID: 33660846
[No Abstract] [Full Text] [Related]
35. Sirolimus as an alternative treatment in patients with granulomatous-lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells.
Deyà-Martínez A; Esteve-Solé A; Vélez-Tirado N; Celis V; Costa J; Cols M; Jou C; Vlagea A; Plaza-Martin AM; Juan M; Alsina L
Pediatr Allergy Immunol; 2018 Jun; 29(4):425-432. PubMed ID: 29532571
[TBL] [Abstract][Full Text] [Related]
36. Soluble Interleukin-2 Receptor Is a Promising Serum Biomarker for Granulomatous Disease in Common Variable Immune Deficiency.
van Stigt AC; Dalm VASH; Nagtzaam NMA; van Rijswijk DA; Barendregt BH; van Hagen PM; IJspeert H; Dik WA
J Clin Immunol; 2021 Apr; 41(3):694-697. PubMed ID: 33404971
[No Abstract] [Full Text] [Related]
37. Glimpses into treating GLILD.
Martelius T; Seppänen MRJ
J Allergy Clin Immunol; 2023 Aug; 152(2):365-367. PubMed ID: 37352977
[No Abstract] [Full Text] [Related]
38. Common Variable Immunodeficiency with the Concomitant Diagnosis of an Inflammatory Myofibroblastic Tumor.
Sewell C; Daniels P; Cottrell J; Hostoffer R
J Clin Immunol; 2021 Jan; 41(1):230-232. PubMed ID: 33017039
[No Abstract] [Full Text] [Related]
39. Editorial: Interstitial Lung Disease in Primary Immunodeficiencies.
Fevang B; Warnatz K; Hurst JR
Front Immunol; 2021; 12():699126. PubMed ID: 34305936
[No Abstract] [Full Text] [Related]
40. Interstitial lung disease in primary immunodeficiency: towards a brighter future.
Hurst JR; Warnatz K;
Eur Respir J; 2020 Apr; 55(4):. PubMed ID: 32245772
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
